for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

J&J files new lawsuit to block biosimilar version of Remicade

Johnson & Johnson has filed a second patent lawsuit against South Korean drug maker Celltrion Inc and Pfizer Inc’s Hospira unit to stop them from launching a cheaper version of J&J’s arthritis and inflammatory bowel drug Remicade in the U.S.

In a lawsuit filed Tuesday in Boston federal court, New Jersey-based J&J’s Janssen Biotech Inc unit claimed that Celltrion has been paying a supplier in Utah to make substances similar to those Janssen uses to grow the cells that produce Remicade, infringing Janssen’s 2009 patent on those substances.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1Q7Gmzl

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up